| Lee, Jin Soo |
NCT06113198 / 2023-000764-58: A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age |
|
|
| Recruiting | 4 | 50 | RoW | rMenB+OMV NZ | GlaxoSmithKline, GlaxoSmithKline Biologicals SA | Meningitis, Meningococcal | 04/26 | 09/26 | | |
Aladdin, NCT04618640: To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 Years |
|
|
| Recruiting | 3 | 249 | RoW | DTaP-IPV combination vaccine | Boryung Biopharma Co., Ltd. | Diphtheria, Tetanus, Pertussis, Poliomyelitis | 12/20 | 07/21 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
NCT06087640: A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age |
|
|
| Recruiting | 3 | 35800 | Europe, RoW | aQIV or aTIV, Fluad Tetra/Quadrivalent or Fluad, QIV or TIV | Seqirus | Influenza, Human | 11/26 | 12/26 | | |
NCT06346184: A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers |
|
|
| Completed | 1 | 37 | RoW | HCP2303, RLD2302, RLD2102 | Hanmi Pharmaceutical Company Limited | Healthy | 06/24 | 06/24 | | |
HM-EMMA-102, NCT06357910: A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions |
|
|
| Completed | 1 | 34 | RoW | HCP2303, RLD2302, RLD2102 | Hanmi Pharmaceutical Company Limited | Healthy | 07/24 | 07/24 | | |
NCT06518122: A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers |
|
|
| Not yet recruiting | 1 | 60 | RoW | HCP1306, RLD2302, RLD2102 | Hanmi Pharmaceutical Company Limited | Healthy | 01/25 | 01/25 | | |
